Publication | Open Access

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

InfertilityFertilityHealth EconomicsMedicineReproductive HealthOutcomes ResearchPharmacoeconomicsBiostatisticsReproductive MedicineCost EffectivenessHuman-derived Follicle-stimulating HormoneMarkov ModelEconomic EvaluationPublic HealthVersus Recombinant Fsh